Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

NCT04669171 is registered in ClinicalTrials.gov with Enterome as lead sponsor.

NCT NCT04669171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma
Lead sponsor
Enterome
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 5, 2021
Completion date
May 30, 2034
Enrollment
80 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, marginal zone lymphoma